Working… Menu

PET/MRI for Men Being Considered for Radiotherapy for Suspected Prostate Cancer Recurrence Post-Prostatectomy (PROPS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02131649
Recruitment Status : Unknown
Verified March 2018 by Glenn Bauman, Lawson Health Research Institute.
Recruitment status was:  Active, not recruiting
First Posted : May 6, 2014
Last Update Posted : March 13, 2018
Information provided by (Responsible Party):
Glenn Bauman, Lawson Health Research Institute

Brief Summary:

The PROPS trial is for men being considered for radiotherapy due to the suspicion that their prostate cancer has recurred following the surgical removal of their prostate (prostatectomy). This suspicion is based on rises seen on Prostate Specific Antigen (PSA) blood tests. Only men who demonstrate the absence of disease on standard imaging scans (Computed Tomography (CT) and bone scans) will be invited to participate.

This study will be assessing if the imaging probe 18-F Fluorocholine (18F-FCH) used during Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) scans, can better predict who will benefit from radiotherapy by identifying the source of cancer recurrence. This will be determined by measuring the number of men who have disease identified outside of the prostate bed (the small pocket or depression where the prostate used to be) on their 18F-FCH PET scan. Since F-18-FCH has been shown to be more sensitive in detecting prostate cancer that may have spread into lymph nodes or bone, it may potentially identify areas of prostate cancer spread not seen with standard imaging.

Condition or disease Intervention/treatment Phase
Prostate Cancer Device: 18F-FCH PET/MRI Scan Not Applicable

Detailed Description:

The study will be a non-randomized, prospective study of men with suspected local recurrence of prostate cancer post-prostatectomy with negative conventional re-staging studies (bone scan and CT of the abdomen and pelvis; MRI of the pelvis as part of re-staging is allowed where it is the institutional standard of care). The clinician will develop an initial treatment plan based on conventional re-staging information.

Patients enrolled onto trial will undergo hybrid PET/MR imaging using 18F-FCH (sites without access to a hybrid PET/MR scanner will conduct a 18F-FCH PET/CT in addition to a full body MRI). A consensus staging report based on local and centralized review of the 18F-FCH PET imaging will be provided to the attending clinician, who will document a second treatment plan based on this additional information. The treatment plan to be implemented (initial or second) will be left to clinician discretion, but will be documented.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 99 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: PROPS (PET/MRI Pre-Radiotherapy for Post-Prostatectomy Salvage)
Actual Study Start Date : February 2015
Actual Primary Completion Date : January 2017
Estimated Study Completion Date : January 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 18F-FCH PET/MRI Scan
Patients will undergo an injection of 18F-fluoromethyl-choline at 3.6 MBq/kg followed by whole body PET/CT imaging. Patients will also undergo a whole body MRI including T2 weighted, Diffusion weighted and Gadolinium Contrast Enhanced sequences. Patients with suspicion for recurrence may undergo biopsy if lesions identified on PET/CT or MRI are accessible for biopsy
Device: 18F-FCH PET/MRI Scan
Patients will first undergo screening to ensure eligibility. If eligible, they will undergo a PET/MRI scan using 18F-FCH as the radiolabeled tracer. If prostate cancer is detected outside the prostate, patients may undergo a biopsy or follow-up 18F-FCH PET/MRI to confirm the results.

Primary Outcome Measures :
  1. Proportion of men with negative or equivocal conventional restaging imaging (bone scan + CT scan of abdomen and pelvis) with uptake identified outside of the prostate bed on 18F-FCH PET [ Time Frame: Within 2 weeks of 18F-FCH PET scan ]

Secondary Outcome Measures :
  1. Biochemical disease free survival at 3 years post-treatment [ Time Frame: 3 years post-treatment ]
    Whether biochemical (PSA) control rates 3 years post-treatment are improved for participants with 18F-FCH PET imaging that was negative or demonstrated uptake confined to the prostate bed and received salvage pelvic radiotherapy compared to published results for men with adverse features.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male, aged 18 years or older.
  • Confirmation of prostate cancer on prostatectomy pathology report.
  • No lymph node involvement (N0 or Nx) reported on prostatectomy pathology report.
  • Documented PSA rise measured on 3 occasions.
  • PSA ≥ 0.2 ng/ml at enrolment.
  • At least one adverse feature: Current PSA > or equal to 1.0, Initial Gleason Grade > or equal to 8, Positive surgical margin, pT3b (seminal vesicle involvement), or PSA doubling time < 10 months.
  • Bone scan and CT scan within 12 weeks of enrolment negative or equivocal for metastatic disease.
  • Suitable candidate for radiotherapy and not yet had any salvage treatment post-prostatectomy.

Exclusion Criteria:

  • Prostate cancer with significant sarcomatoid or spindle cell or neuroendocrine small cell components.
  • Proven metastatic disease.
  • Patients who refuse salvage prostate bed radiotherapy.
  • Patients who refuse to join the trial or are unable to consent.
  • Patients not being considered for further therapy.
  • Patients who cannot lie still for at least 30 minutes or comply with imaging.
  • Unequivocal evidence of disease outside the prostate bed on conventional imaging
  • Allergy to MRI contrast agent (exclusion for MRI component only) or PET tracer to be used as part of the imaging
  • Sickle cell disease or other anemias
  • Insufficient renal function (eGFR < 30 mL/min/1.73 m2)
  • Residual bladder volume > 150 cc (determined by post-void ultrasound)
  • Hip prosthesis, vascular grafting or other conditions affecting imaging or delivery of therapeutic radiation
  • Contraindication to MRI, including but not restricted to: pacemaker or other electronic implants, known metal in the orbit, MR incompatible surgical or cerebral aneurysm clips, Shrapnel, tattoos, non-removable body piercings (relative contraindications)
  • Hormone Androgen deprivation therapy of any type within 6 months prior to enrollment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02131649

Layout table for location information
Australia, New South Wales
St. Vincent's Hospital
Sydney, New South Wales, Australia, 2010
Australia, Victoria
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia, 3002
Austin Hospital
Melbourne, Victoria, Australia, 3084
Eastern Health
Melbourne, Victoria, Australia, 3128
Canada, Ontario
Lawson Health Research Institute, London Health Sciences Centre
London, Ontario, Canada, N6A 5W9
University of Toronto
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Universite Laval Quebec
Laval, Quebec, Canada, G1V 0A6
United Kingdom
Velindre Cancer Centre
Cardiff, South Glamorgan, United Kingdom
University College London Hospital
London, United Kingdom, NW1 2BU
Royal Marsden Hospital
London, United Kingdom, SW3 6JJ
Sponsors and Collaborators
Lawson Health Research Institute
Layout table for investigator information
Principal Investigator: Glenn Bauman, MD London Regional Cancer Program
Layout table for additonal information
Responsible Party: Glenn Bauman, Principal Investigator, Lawson Health Research Institute Identifier: NCT02131649    
Other Study ID Numbers: GAP02-01.1
First Posted: May 6, 2014    Key Record Dates
Last Update Posted: March 13, 2018
Last Verified: March 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Glenn Bauman, Lawson Health Research Institute:
Prostate Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases